Practice of HPV Vaccine and Associated Factors among School Girls in Melaka, Malaysia

  • Al-Naggar, Redhwan Ahmed ;
  • Bobryshev, Yuri V. ;
  • Al-Jashamy, Karim ;
  • Al-Musli, Mahfoudh
  • Published : 2012.08.31


Objective: The objective of this study is to determine the practice and associated factors of HPV vaccine among school girls in Melaka, Malaysia. Methodology: A total number of 612 secondary school girls participated in this study. The questionnaire consists of 38 questions which included 3 sections. The first section is about socio-demography. The Second section is about knowledge and awareness of HPV vaccines. The third section is about practices with associated barriers of HPV vaccination. Verbal consent was obtained from all participants, and data were analyzed using SPSS 13. Results: A total number of 612 secondary school girl students participated in this study. The mean age was $13.93{\pm}SD$ (1.09); minimum age was 13 years old and maximum was 17 years old. The majority of them was Malay, from rural areas and had a family monthly income of RM 3000 or less (91.8%, 53.1%, 69.6%; respectively). The majority of the parents of the school girls were with secondary education level (56.4%). The majority of the participants did not have a family history of cervical cancer (99.0%). The prevalence of HPV vaccination was 77.9% among school girls in Melaka. The majority of the participants were vaccinated in their schools (77.0%). About 69% knew about cervical cancer and 77.6% had ever heard about HPV vaccine. Regarding the factors that influence the practice of uptake HPV vaccine, they were age, race, income, parents' education, knowledge about cervical cancer, heard about HPV vaccine and place of getting the vaccine (p<0.001). Conclusions: The prevalence of HPV vaccine among school girls is high. Age, race, income, parents' education, knowledge about cervical cancer, heard about HPV vaccine and place of getting the vaccine were the significant factors that influence the practice of uptake HPV vaccine among school girls.


HPV vaccine;practice;associated factors


  1. Adams M, Jasani B, Fiander A (2007). Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine, 25, 3007-13.
  2. Agius PA, Pitts MK, Smith AM, Mitchell A (2010). Human papillomavirus and cervical cancer: Gardasil vaccination status and knowledge amongst a nationally representative sample of Australian secondary school students. Vaccine, 28, 4416-22.
  3. Al-Dubai SA, Alshagga MA, Al-Naggar RA, et al (2010). Knowledge, attitudes and barriers for human papilloma virus (HPV) vaccines among Malaysian women. Asian Pac J Cancer Prev, 11, 887-92.
  4. Allen JD, Othus MK, Shelton RC, et al (2010). Parental decision making about the HPV vaccine. Cancer Epidemiol Biomarkers Prev, 19, 2187-98.
  5. Al-Naggar RA (2012). Acceptance and Associated factors of HPV Vaccination among Young Male Malaysians. J Community Med Health Edu (in press).
  6. Al-Naggar RA, Bobryshev YV (2011). Practice towards Human Papillomavirus Vaccine among Malaysian Women: A survey of the General Population. Asian Pac J Cancer Prev, 12, 2045-9.
  7. Al-Naggar RA, Karim Al-Jashamy K, Chen R (2010) Perceptions and Opinions towards Human Papilloma Virus Vaccine among Young Women. Asian Pac J Cancer Prev, 11, 1515-9.
  8. Ault KA (2007). Effect of prophylactic human papillomavirus L1 virus-likeparticle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet, 369, 1861-8.
  9. Benard VB, Johnson CJ, Thompson TD, et al (2008). Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. Cancer, 113, 2910-8.
  10. Bigham M, Remple VP, Pielak K, et al (2006). Uptake and behavioural and attitudinal determinants of immunization in an expanded routine infant hepatitis B vaccination program in British Columbia. Can J Public Health, 97, 90-5.
  11. Bosch FX, de Sanjose S (2003). Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality. J Natl Cancer Inst Monogr, 31, 3-13.
  12. Brewer NT, Fazekas KI (2007). Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med, 45, 107-14.
  13. Brewer NT, Gottlieb SL, Reiter PL, et al (2011). Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis, 38, 197-204.
  14. Bynum SA, Brandt HM, Patricia A, et al (2011). Working to close the gap: Identifying predictors of HPV vaccine uptake among young African American women. J Health Care Poor Underserv, 22, 549-61.
  15. Caskey R, Lindau ST, Alexander GC (2009). Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health, 45, 453-62.
  16. Centers for Disease (2010). Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years—United States, 2009. MMWR Morbidity & Mortality Weekly Report, 59, 1018-23.
  17. Chao C, Velicer C, Slezak JM, Jacobsen SJ (2010). Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol, 171, 357-67.
  18. Constantine NA, Jerman P (2007). Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health, 40, 108-15.
  19. Cook RL, Zhang J, Mullins J, et al (2010) Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. J Adolesc Health, 47, 596 -9.
  20. Daley MF, Liddon N, Crane LA, et al (2006). A National Survey of Pediatrician Knowledge and Attitudes Regarding Human Papillomavirus Vaccination. Pediatrics, 118, 2280-9.
  21. Davis K, Dickman ED, Ferris D, Dias JK (2004). Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis, 8, 188-94.
  22. Dempsey A, Cohn L, Dalton V, Ruffin M (2010). Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine, 28, 989-95.
  23. Dunne EF, Unger ER, Sternberg M, et al (2007). Prevalence of HPV infection among females in the United States. JAMA, 297, 813-9.
  24. Ferlay J, Bray F, Pisani P, Parkin D Globocan (2004). Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base, 5 version 2.0 IARC Press, Lyon.
  25. Garland SM, Hernandez-Avila M, Wheeler CM, et al (2007). Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med, 356,1928-43.
  26. Gerend MA, Weibley E, Bland H (2009). Parental response to human papillomavirus vaccine availability: uptake and intentions. J Adolesc Health, 45, 528-31.
  27. Greer CE, Wheeler CM, Ladner MB, et al (1995). Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol, 33, 2058-63.
  28. Jain N, Euler GL, Shefer A, et al (2009). Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult. Prev Med, 48, 426-31.
  29. Kahn JA, Rosenthal SL, Hamann T, et al (2003). Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS, 14, 300-6.
  30. Kahn JA, Zimet GD, Bernstein DI, et al (2005). Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health, 37, 502-10.
  31. Kim YT (2009). Current status of cervical cancer and HPV infection in Korea. J Gynecol Oncol, 20, 1Y7.
  32. Kitchener HC, Almonte M, Wheeler P, el al (2006). HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer, 95, 56-61.
  33. Lee GM, Santoli JM, Hannan C, et al (2007). Gaps in vaccine fınancing for underinsured children in the U.S. JAMA, 298, 638-43.
  34. Lenehan JG, Leonard KC, Nandra S, et al (2008). Women's knowledge, attitudes, and intentions concerning human papillomavirus vaccination: findings of a waiting room survey of obstetrics gynaecology outpatients. J Obstet Gynaecol Canada, 30, 489-99.
  35. Lim GCC, Halimah Y (2004). Second report of the national cancer registry. Cancer. Incidence in malaysia 2003. Kuala lumpur: national cancer registry.
  36. Lyn-Cook R, Halm EA, Wisnivesky J P (2007). Determinants of adherence to influenza vaccination among inner-city adults with persistent asthma. Primary Care Respiratory J, 16, 229-35.
  37. Madhivanan P, Krupp K, Yashodha MN, et al (2009). Attitudes toward HPV vaccination among parents of adolescent girls in Mysore, India. Vaccine, 27, 5203-8.
  38. Mathur MB, Mathur VS, Reichling DB (2010). Participation in the decision to become vaccinated against human papillomavirus by California High School girls and the predictors of vaccine status. J Pediatric Health Care, 24, 14-24.
  39. McLaughlin CG, Wyszewianski L (2002). Access to care: remembering old lessons. Health Serv Res, 6, 1441-3.
  40. National, state, and local area vaccination coverage among adolescents aged 13-17 years—United States, 2008. MMWR Morb Mortal Wkly Rep, 58, 997-1001.
  41. National, state, and local area vaccination coverage among adolescents aged 13-17 years—United States, 2009. MMWR Morb Mortal Wkly Rep, 59, 1018-23.
  42. Nelson A (2002). Unequal treatment: Confronting racial and ethnic disparities in health care. J Natl Med Assoc, 94, 666-8.
  43. Neubrand TPL, Breitkopf CR, Rupp R, Breitkopf D, Rosenthal SL (2009). Factors associated with completion of the human papillomavirus vaccine series. Clin Pediatr, 48, 966 -9.
  44. Niccolai LM, Mehta NR , Hadler JH (2011). Racial/Ethnic and Poverty Disparities in Human Papillomavirus Vaccination Completion. Am J Prev Med (in press).
  45. Ogilvie G, Anderson M, Marra F, et al (2010). A populationbased evaluation of a publicly funded, school based HPV vaccine program in British Columbia, Canada: parental factors 580 associated with HPV vaccine receipt. PLoS Medicine, 7, 5.
  46. Paavonen J, Jenkins D, Bosch FX, et al (2007). Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet, 369, 2161-70.
  47. Pruitt SL, Schootman M (2010). Geographic disparity, area poverty, and human papillomavirus vaccination. Am J Prev Med, 38, 525-33.
  48. Reiter PL, Cates JR, McRee AL, et al (2010). Statewide HPV vaccine initiation among adolescent females in North Carolina. Sex Transm Dis, 37, 549-56.
  49. Richardson H, Kelsall G, Tellier P, et al (2003). The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev, 12, 485-90.
  50. Riedesel JM, Rosenthal SL, Zimet GD, et al (2005). Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol, 18, 391-8.
  51. Roberts SA, Brabin L, Stretch R, et al (2011). Human papillomavirus vaccination and social inequality: results from a prospective cohort study. Epidemiol Infect, 139, 400-5.
  52. Rosenthal SL, Rupp R, Zimet GD, et al (2008). Uptake of HPV vaccine: demographics, sexual history and values, parenting style, and vaccine attitudes. J Adolesc Health, 43, 239-45.
  53. Sauvageau C, Bernard D, Vladimir G, et al (2007). Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec. BMC Public Hlth, 7, 304.
  54. Seo K, Oh JK, Shin H (2008). Efficacy of human papillomavirus vaccines as an anticancer vaccine. J Korean Soc Matern Child Health, 12, 1-7.
  55. Shahrabani S, Benzion U, Yom Din G (2009). Factors affecting nurses' decision to get the flu vaccine. Eur J Health Econ, 10, 227-31.
  56. Smith LM, Brassard P, Kwong JC, et al (2011). Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an ontario cohort of grade 8 girls. BMC Public Health, 11, 645.
  57. Social Statistics Bulletin, Malaysia (2005). Kuala Lumpur: Department of Statistics, Malaysia.
  58. Songthap A, Pitisuttithum P, Kaewkungwal J, et al (2009). Knowledge, attitudes, and acceptability of a human papillomavirus vaccine among healthcare providers. Southeast Asian J Trop Med Public Health, 40, 1048-56.
  59. Syrjänen S, Shabalova I, Petrovichev N, et al (2005). Cohort Study Group Age-specific incidence and clearance of highrisk human papillomavirus infections in women in the former Soviet Union. Int J STD AIDS, 16, 217-23.
  60. Villa LL, Costa RLR, Petta CA, et al (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6, 271-8.
  61. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.<12::AID-PATH431>3.0.CO;2-F
  62. Widdice LE, Bernstein DL, Leonard AC, Marsolo KA, Kahn JA (2011). Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics, 127, 77-84.
  63. Wong CA, Berkowitz Z, Dorell CG, et al (2008). Human Papillomavirus Vaccine Uptake Among 9- to 17-Year-Old Girls. Cancer, 117, 5612-20.
  64. Wong LP, Wong YL, Low WY, et al (2009). Knowledge and awareness of cervical cancer and screening among Malaysian women who have never had a Pap smear: a qualitative study. Singapore Med J, 50, 49-53.
  65. Yeganeh N, Curtis D, Kuo A (2010). Factors influencing HPV vaccination status in a Latino population; and parental attitudes towards vaccine mandates. Vaccine, 28, 4186-91.
  66. Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B (2006). Chapter 24: psychosocial aspects of vaccine acceptability. Vaccine, 24, 201-9.
  67. Zimet GD, Weiss TW, Rosenthal SL, et al (2010). Reasons for non-vaccination against HPV and future vaccination intentions among 19-26 year-old women. BMC Women's Health, 10, 27.

Cited by

  1. Determination of Knowledge of Turkish Midwifery Students about Human Papilloma Virus Infection and its Vaccines vol.14, pp.11, 2013,
  2. Acceptability of Human Papilloma Virus Vaccination among Women in the United Arab Emirates vol.15, pp.5, 2014,
  3. The Uptake of Human Papillomavirus Vaccination and Its Associated Factors Among Adolescents: A Systematic Review pp.2150-1327, 2017,
  4. Awareness of and willingness to be vaccinated by human papillomavirus vaccine among junior middle school students in Jinan, China pp.2164-554X, 2017,
  5. Using the health belief model to assess beliefs and behaviors regarding cervical cancer screening among Saudi women: a cross-sectional observational study vol.19, pp.1, 2019,